AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins Read More
Avacta shares up as flow tests receive CE mark for self-test use Read More
Avacta confirms lateral flow tests can detect Omicron variant Read More
IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US Read More
Avacta and Novacyt await UK regulatory approval for Covid-19 tests Read More
Avacta hails "transformative" first half despite widening loss Read More
Avacta sees pre-clinical development milestone in LG Chem partnership Read More
UK earnings, trading statements calendar - next 7 days Read More
IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO Read More
IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board Read More
Avacta doses first patient in chemotherapy medication trial Read More
IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts Read More
AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down Read More
IN BRIEF: Avacta wins manufacturer certification for lateral flow test Read More
IN BRIEF: Avacta's lateral flow test detects Covid Delta variant Read More
AIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs Read More
AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers Read More
IN BRIEF: Avacta signs distribution deal for its Covid test Read More
UK shareholder meetings calendar - next 7 days Read More
Avacta Covid lateral flow test gets regulatory green light in EU Read More
